Table 2.
Disease response, control, and progression rates a in response-evaluable patients with and without cutaneous toxicity (n = 51)
|
N (%) |
||||
|---|---|---|---|---|
| Pts without cutaneous toxicity (N = 25) | Pts with cutaneous toxicity (N = 26) | Risk difference (95% CI) (toxicity vs nontoxicity) | p value | |
| Disease response | 6 (24.0) | 15 (57.7) | 33.7% (5.6%–57.9%) | 0.0145 |
| CR | – | 3 (11.5) | 11.5% (–3.9% to 30.6%) | 0.2353 |
| PR | 6 (24.0) | 12 (46.2) | 22.2% (–4.9% to 47.0%) | 0.0979 |
| Disease control | 16 (64.0) | 19 (73.1) | 9.1% (–17.1% to 34.9%) | 0.4849 |
| SD | 10 (40.0) | 4 (15.4) | –24.6% (–48.4% to 0.8%) | 0.0644 |
| MR | – | 3 (11.5) | 11.5% (–3.9% to 30.6%) | 0.2353 |
| PD | 9 (36.0) | 4 (15.4) | –20.6% (–44.9% to 4.0%) | 0.1164 |
CI = confidence interval; CR = complete response; MR = mixed response; PD = disease progression; PR = partial response; Pts = patients; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease; UTUC = upper tract urothelial carcinoma.
a
Based on best physician-determined RECIST response.